2770-7296

Neuroprotection

Wiley (John Wiley & Sons)

View prefix report (10.1002)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 40 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact40 DOIs
2

Attach ORCID iDs across 28 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact28 DOIs
3

Deposit reference lists for 26 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact26 DOIs

DOIs for this ISSN

Showing the top 5 of 110 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Novel therapeutic strategies and common mechanisms of neurod… (10.1002/nep3.52)
Abstract ORCID
38.91 5
2 Tolerability and first hints for potential efficacy of motor… (10.1002/nep3.47)
ORCID
25.00 9
3 Protecting the brain from multifaceted damage and promoting… (10.1002/nep3.70003)
Abstract
19.45 5
4 Neurodegeneration in acute and chronic central nervous syste… (10.1002/nep3.69)
Abstract
11.93 2
5 Exploring novel experimental treatments for major neurodegen… (10.1002/nep3.31)
Abstract
7.53 1
6 Better understanding complex pathomechanisms in central nerv… (10.1002/nep3.70017)
Abstract
7.53 1
7 A holistic view on disease‐modifying aspects, comorbidities,… (10.1002/nep3.70023)
Abstract
7.53 1
8 Join us on an amazing journey towards next‐generation treatm… (10.1002/nep3.8)
Abstract
7.53 1
9 Issue Information (10.1002/nep3.10)
Abstract References ORCID
0.00 0
10 Issue Information (10.1002/nep3.11)
Abstract References ORCID
0.00 0
11 Ex vivo 100 μm isotropic diffusion MRI‐based tractography of… (10.1002/nep3.14)
0.00 3
12 Exploiting moderate hypoxia to benefit patients with brain d… (10.1002/nep3.15)
0.00 18
13 Issue Information (10.1002/nep3.16)
Abstract References ORCID
0.00 0
14 Issue Information (10.1002/nep3.17)
Abstract References ORCID
0.00 0
15 Issue Information (10.1002/nep3.18)
Abstract References ORCID
0.00 0
16 Issue Information (10.1002/nep3.19)
Abstract References ORCID
0.00 0
17 3D printing‐based frugal manufacturing of glass pipettes for… (10.1002/nep3.20)
0.00 5
18 Liquid–liquid phase separation in synaptopathies (10.1002/nep3.21)
0.00 1
19 Monocytes in neonatal stroke and hypoxic‐ischemic encephalop… (10.1002/nep3.22)
0.00 4
20 Preserving cognitive function in patients with Alzheimer's d… (10.1002/nep3.23)
0.00 26
21 Neurological manifestations with jugular vein thrombosis lin… (10.1002/nep3.24)
0.00 1
22 Activation of neurogenesis in the hippocampus is a novel the… (10.1002/nep3.25)
0.00 8
23 Attenuation of amyotrophic lateral sclerosis via stem cell a… (10.1002/nep3.26)
0.00 1
24 The potential of a combined cell‐based therapy and rehabilit… (10.1002/nep3.27)
0.00 6
25 Activation of dopamine 2 receptors modulates glutamate decar… (10.1002/nep3.28)
0.00 1
26 Mononuclear cell therapy of neonatal hypoxic‐ischemic enceph… (10.1002/nep3.29)
0.00 0
27 Mesenchymal stem cell‐derived exosomes: Shaping the next era… (10.1002/nep3.30)
0.00 25
28 Mechanisms of glutamate metabolic function and dysfunction i… (10.1002/nep3.32)
0.00 12
29 Lists of Reviewers (10.1002/nep3.33)
Abstract References ORCID
0.00 0
30 Stress enhances expression of calcium‐binding proteins and N… (10.1002/nep3.35)
0.00 5
31 Intracranial pressure is elevated at 24 h post‐stroke in mic… (10.1002/nep3.36)
0.00 2
32 Beyond boundaries: Neuroprotective effects of steroids and e… (10.1002/nep3.37)
0.00 2
33 Role of autoreactive Tc17 cells in the pathogenesis of exper… (10.1002/nep3.38)
0.00 1
34 The dual role of microglia in ischemic stroke and its modula… (10.1002/nep3.39)
0.00 24
35 Neuroprotective effects of repetitive transcranial magnetic… (10.1002/nep3.40)
0.00 3
36 Mitigating the impact of mechanisms causing neuronal degener… (10.1002/nep3.41)
Abstract
0.00 0
37 Research progress on intranasal treatment for Parkinson's di… (10.1002/nep3.42)
0.00 13
38 Targeting brain‐derived neurotrophic factor in the treatment… (10.1002/nep3.43)
0.00 20
39 Role of gut microbiota in ischemic stroke: A narrative revie… (10.1002/nep3.44)
0.00 9
40 The role of angiotensin II type 1 receptor pathway in cerebr… (10.1002/nep3.45)
0.00 6
41 Glutamate and excitotoxicity in central nervous system disor… (10.1002/nep3.46)
0.00 70
42 Issue Information (10.1002/nep3.48)
Abstract References ORCID
0.00 0
43 Issue Information (10.1002/nep3.50)
Abstract References ORCID
0.00 0
44 Issue Information (10.1002/nep3.51)
Abstract References ORCID
0.00 0
45 Five percent CO<sub>2</sub> inhalation alleviates hippocampa… (10.1002/nep3.53)
0.00 0
46 Interleukin‐6 induces cognitive impairment via toll‐like rec… (10.1002/nep3.54)
0.00 6
47 Impact of neutrophil‐to‐lymphocyte ratio on the effect of hy… (10.1002/nep3.55)
0.00 5
48 Microglial senescence in neurodegeneration: Insights, implic… (10.1002/nep3.56)
0.00 16
49 Effects of immunological processes and mild ambient atmosphe… (10.1002/nep3.57)
Abstract
0.00 0
50 Blood‐based biomarkers of Alzheimer's disease: Standardizati… (10.1002/nep3.58)
0.00 7